Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O94768
UPID:
ST17B_HUMAN
Alternative names:
DAP kinase-related apoptosis-inducing protein kinase 2
Alternative UPACC:
O94768
Background:
Serine/threonine-protein kinase 17B, also known as DAP kinase-related apoptosis-inducing protein kinase 2, plays a crucial role in cellular processes by phosphorylating myosin light chains. This kinase acts as a positive regulator of apoptosis, indicating its significant role in cell death and survival mechanisms.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase 17B could open doors to potential therapeutic strategies. Its involvement in apoptosis regulation highlights its potential as a target for therapeutic intervention in diseases where apoptosis is dysregulated.